scispace - formally typeset
C

Charlie D. Chen

Researcher at Laboratory of Molecular Biology

Publications -  43
Citations -  5965

Charlie D. Chen is an academic researcher from Laboratory of Molecular Biology. The author has contributed to research in topics: Demethylase & Histone. The author has an hindex of 18, co-authored 39 publications receiving 5487 citations. Previous affiliations of Charlie D. Chen include Chinese Academy of Sciences & University of California, Los Angeles.

Papers
More filters
Journal ArticleDOI

Molecular determinants of resistance to antiandrogen therapy

TL;DR: Using microarray-based profiling of isogenic prostate cancer xenograft models, it is found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy.
Journal ArticleDOI

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

TL;DR: The diarylthiohydantoins RD162 and MDV3100 are characterized, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression that appear to be promising candidates for treatment of advanced prostate cancer.
Journal ArticleDOI

JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer

TL;DR: JARID1B is identified as a demethylase capable of removing three methyl groups from histone H3 lysine 4 and up-regulated in prostate cancer and associates with androgen receptor and regulates its transcriptional activity.
Journal ArticleDOI

JMJD3 is a histone H3K27 demethylase.

TL;DR: JMJD3 is identified as a demethylase capable of removing the trimethyl group from histone H3 lysine 27 and upregulated in prostate cancer and its expression is higher in metastatic prostate cancer.
Journal ArticleDOI

Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer

TL;DR: It is established that PTEN and IGF BP-2 expression are inversely correlated in human brain and prostate cancers and implicate serum IGFBP-2 levels as a potential serum biomarker of PTEN status and PI3K Akt pathway activation in cancer patients.